Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% --

-- Several key milestones advance 5x30 path to growth and value creation --